Ascendis Pharma A/S (ASND) News Today $175.54 +0.15 (+0.08%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASND Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Massachusetts Financial Services Co. MA Buys 10,366 Shares of Ascendis Pharma A/S (NASDAQ:ASND)July 15 at 6:44 AM | marketbeat.comNew 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of LifeJuly 14 at 4:01 PM | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Rice Hall James & Associates LLCJuly 14 at 6:35 AM | marketbeat.comDiversify Wealth Management LLC Acquires Shares of 5,994 Ascendis Pharma A/S (NASDAQ:ASND)July 13, 2025 | marketbeat.comCitigroup Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock PriceJuly 13, 2025 | americanbankingnews.comBrown Advisory Inc. Has $4.03 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)July 12, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Position Decreased by Crossmark Global Holdings Inc.July 12, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $243.00July 11, 2025 | marketbeat.comPenserra Capital Management LLC Purchases New Position in Ascendis Pharma A/S (NASDAQ:ASND)July 11, 2025 | marketbeat.comAscendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025July 8, 2025 | finance.yahoo.comAscendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025July 7, 2025 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Earns Overweight Rating from Analysts at Morgan StanleyJuly 3, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 3, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Has $28.71 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)July 2, 2025 | marketbeat.comASND Ascendis Pharma A/S - Seeking AlphaJune 29, 2025 | seekingalpha.comAscendis Pharma Closes Warrant Exercise Window, Boosts Share CapitalJune 27, 2025 | tipranks.comDiversified Trust Co Has $7.26 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)June 27, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Trading Down 6.6% - Here's WhyJune 25, 2025 | marketbeat.comPursue Wealth Partners LLC Takes $226,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)June 23, 2025 | marketbeat.comAscendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone ProspectsJune 17, 2025 | msn.comBofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy RatingJune 17, 2025 | msn.comHandelsbanken Fonder AB Sells 2,100 Shares of Ascendis Pharma A/S (NASDAQ:ASND)June 15, 2025 | marketbeat.comAscendis Pharma price target raised to $224 from $215 at OppenheimerJune 14, 2025 | finance.yahoo.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Oppenheimer Analyst SaysJune 13, 2025 | marketbeat.comTransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26June 11, 2025 | insidermonkey.comAscendis Pharma price target raised to $216 from $201 at BofAJune 10, 2025 | msn.comCantor Fitzgerald Weighs in on ASND FY2026 EarningsJune 10, 2025 | marketbeat.comToth Financial Advisory Corp Buys Shares of 5,335 Ascendis Pharma A/S (NASDAQ:ASND)June 10, 2025 | marketbeat.comBank of America Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $216.00June 9, 2025 | marketbeat.comTransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH TrialJune 9, 2025 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Buy" by BrokeragesJune 8, 2025 | marketbeat.comIs Ascendis Pharma Gaining or Losing Market Support?June 5, 2025 | benzinga.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Two Sigma Investments LPJune 4, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Up 8.6% - Should You Buy?June 3, 2025 | marketbeat.comAscendis Pharma ADR Scores Relative Strength Rating UpgradeJune 3, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Given New $201.00 Price Target at Bank of AmericaJune 3, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Two Sigma Advisers LPJune 3, 2025 | marketbeat.comAscendis Pharma stock rises following FDA priority reviewJune 2, 2025 | investing.comAscendis Pharma Rises as FDA Grants Priority Review for Achondroplasia TreatmentJune 2, 2025 | msn.comFDA Accepts TransCon® CNP NDA for Priority ReviewJune 2, 2025 | globenewswire.comGAMMA Investing LLC Has $142.60 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)June 2, 2025 | marketbeat.comBank of America Corp DE Sells 6,037,189 Shares of Ascendis Pharma A/S (NASDAQ:ASND)June 1, 2025 | marketbeat.comAscendis Pharma’s SWOT analysis: strong product pipeline drives stock potentialMay 27, 2025 | investing.comVoloridge Investment Management LLC Decreases Stake in Ascendis Pharma A/S (NASDAQ:ASND)May 23, 2025 | marketbeat.comWoodline Partners LP Has $43.73 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)May 22, 2025 | marketbeat.comZimmer Partners LP Has $13.34 Million Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)May 22, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Holdings Boosted by Vestal Point Capital LPMay 21, 2025 | marketbeat.comSoleus Capital Management L.P. Makes New $19.82 Million Investment in Ascendis Pharma A/S (NASDAQ:ASND)May 21, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)May 20, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Buy" from AnalystsMay 16, 2025 | marketbeat.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼1.280.96▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼117▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARGX News Today ONC News Today BNTX News Today INSM News Today SMMT News Today TEVA News Today ITCI News Today GMAB News Today MRNA News Today RDY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
